fashion -WSS

fashion

author：hotspot 2025-10-02 21:05:19 - browse：7

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： CDC recommends rationing of RSV shot due to shortages

hotspot

WSS

FDA has safety concerns on CRISPR

Meta's Zuckerberg and Chan on track to put $50 billion into science

First Opinion Podcast: How to protect health care in times of war

Ultragenyx gene therapy for rare liver ailment succeeds in late

See how much Covid

Woman returns to dialysis after doctors remove transplanted pig kidney

leisure time

fashion

hotspot

23andMe had bad news about my health. I wish a person had delivered it

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Traditional Chinese medicine benefits explored in new JAMA study

Anesthesiologist group: stop taking Ozempic before surgery

FDA has safety concerns on CRISPR

Novavax promises a turnaround & Lilly roils the obesity market

Change Healthcare can notify patients about the breach, HHS says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HIV drugs protect against transmission, even in unprotected sex

Wikipedia

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

The FDA weighs the risks of candy

With trial win, GSK could get blood cancer drug back on market

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

hotspot

focus

hotspot

entertainment